90 related articles for article (PubMed ID: 22623417)
1. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
2. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M
Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927
[TBL] [Abstract][Full Text] [Related]
3. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
6. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
[TBL] [Abstract][Full Text] [Related]
7. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
[TBL] [Abstract][Full Text] [Related]
8. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
9. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor.
Thomas F; Holly JM; Persad R; Bahl A; Perks CM
Prostate; 2010 Jun; 70(8):856-65. PubMed ID: 20127733
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
11. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
14. Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
Ramachandran K; Speer C; Nathanson L; Claros M; Singal R
Anticancer Res; 2016 Jan; 36(1):161-8. PubMed ID: 26722040
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
16. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Suzuki E; Kikuchi E; Oya M
J Urol; 2011 Jun; 185(6):2376-81. PubMed ID: 21511293
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
18. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
20. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
